UCB and Sanofi-Aventis have announced US Food and Drug Administration (FDA) approval for Xyzal oral solution, for the relief of indoor and outdoor allergies and hives for children aged two years and older.
FDA approval gives the green light for the relief of symptoms of perennial allergic rhinitis (indoor allergies) and chronic idiopathic urticaria (chronic hives) and for symptoms of seasonal allergic rhinitis (outdoor allergies).
Until now, Xyzal oral solution had only been approved as an allergy treatment for children aged six years and older.
University of Tennessee Health Science Centre clinical professor of paediatrics and medicine Michael Blaiss said that XYZAL provides caregivers with a new treatment option that can help relieve nasal allergy symptoms in young patients once diagnosed by a physician.
Nasal allergies are the most common chronic condition found in children, with allergic rhinitis believed to affect as many as 40% of US children.